Novartis Chief Executive Vas Narasimhan warned on Tuesday that U.S. Drug pricing policies under the Trump administration have created a “very demanding situation” for the pharmaceutical industry, signaling growing tensions between major drugmakers and federal regulators over cost controls.
The Swiss-based pharmaceutical giant, one of the world’s largest by revenue, has been at the center of debates over drug affordability in the U.S., where prescription prices remain among the highest globally. Narasimhan’s remarks, delivered during a conference call with investors, underscored the industry’s unease with policies that could limit pricing flexibility—a cornerstone of pharmaceutical profitability.
“The current environment in the U.S. Is extremely challenging,” Narasimhan said, according to a transcript reviewed by The Wall Street Journal. “We’re seeing increasing pressure on pricing, and the regulatory landscape is becoming more restrictive. This represents a very difficult situation for innovation-driven companies like ours.”
Policy Shifts Under Scrutiny
The Trump administration has pursued several measures aimed at lowering drug costs, including proposals to tie Medicare reimbursement rates to prices paid in other developed countries—a policy known as international reference pricing. The Department of Health and Human Services (HHS) has also advanced rules requiring drugmakers to disclose list prices in television advertisements, a move the industry has fiercely opposed.
Novartis, which reported $53 billion in global sales last year, has been particularly vocal about the potential impact of these policies. The company’s portfolio includes high-profile drugs like the heart failure medication Entresto and the gene therapy Zolgensma, which carries a list price of $2.1 million per treatment. Industry analysts have warned that price caps or mandatory discounts could reduce revenue streams critical for funding research and development.
In a separate development, the U.S. Food and Drug Administration (FDA) has accelerated approvals for generic and biosimilar drugs, intensifying competition in markets once dominated by brand-name manufacturers. While these measures aim to increase access to affordable medications, pharmaceutical executives argue they could stifle investment in next-generation therapies.
Industry Pushback and Political Divides
Narasimhan’s comments reflect broader industry concerns about the sustainability of current pricing models. The Pharmaceutical Research and Manufacturers of America (PhRMA), the industry’s leading trade group, has lobbied aggressively against proposed reforms, arguing they would undermine innovation. In a statement last month, PhRMA CEO Stephen Ubl called the administration’s policies “short-sighted,” warning they could lead to fewer breakthrough treatments.
Political divisions over drug pricing have sharpened ahead of the 2024 election. While Democrats have largely supported stricter cost controls, Republicans have expressed concerns about government overreach. Some lawmakers, including Senate Finance Committee Chair Ron Wyden (D-Ore.), have proposed legislation to allow Medicare to negotiate prices directly with drugmakers—a move Narasimhan has described as “a step too far.”
Novartis is not alone in its criticism. Executives at Pfizer, Merck, and Eli Lilly have also raised alarms about the financial impact of pricing reforms, particularly on smaller biotech firms reliant on venture capital funding. A report by the Congressional Budget Office (CBO) earlier this year estimated that international reference pricing could save Medicare $50 billion over a decade but cautioned that it might also reduce the number of new drugs entering the market.
Global Implications
The U.S. Market accounts for nearly half of Novartis’ revenue, making it a critical battleground for the company’s growth strategy. Narasimhan has previously emphasized the need for “predictable” regulatory environments to justify long-term investments in drug development. In contrast, European countries with stricter price controls have seen slower adoption of cutting-edge therapies, a trend that industry leaders cite as a cautionary tale.
Novartis has responded to pricing pressures by shifting its focus toward high-value, specialized treatments, such as cell and gene therapies. The company’s pipeline includes 200 projects in clinical development, with a particular emphasis on oncology and rare diseases. Although, Narasimhan acknowledged that the current policy climate could force difficult trade-offs between profitability and patient access.
“We’re committed to bringing innovative medicines to patients, but we need a framework that supports both affordability and sustainability,” he said. “The U.S. Has historically been a leader in biomedical innovation, and we hope policymakers will recognize the risks of overregulation.”
As of Tuesday, the White House had not responded to requests for comment on Narasimhan’s remarks. The Centers for Medicare & Medicaid Services (CMS) is expected to release updated guidance on drug pricing reforms later this quarter, though the timeline for implementation remains uncertain.
